MA34212B1 - Composés hétérocycliques et leurs utilisations - Google Patents
Composés hétérocycliques et leurs utilisationsInfo
- Publication number
- MA34212B1 MA34212B1 MA35338A MA35338A MA34212B1 MA 34212 B1 MA34212 B1 MA 34212B1 MA 35338 A MA35338 A MA 35338A MA 35338 A MA35338 A MA 35338A MA 34212 B1 MA34212 B1 MA 34212B1
- Authority
- MA
- Morocco
- Prior art keywords
- inflammatory
- acute
- disorders
- diseases
- limited
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des hétéroaryles bicycliques substitués et des compositions contenant ceux-ci, pour le traitement de l'inflammation générale, de l'arthrite, de maladies rhumatismales, de l'arthrose, de troubles intestinaux inflammatoires, de troubles ophtalmiques inflammatoires, de troubles inflammatoires ou instables de la vessie, du psoriasis, de troubles de la peau avec des composantes inflammatoires, d'affections inflammatoires chroniques, comprenant mais non restreintes à des maladies auto-immunes telles que le lupus érythémateux disséminé (SLE), la myasténie gravis, la polyarthrite rhumatoïde, l'encéphalomyélite disséminée aiguë, le purpura thrombocytopénique idiopathique, la sclérose en plaques, le syndrome de Sjögren et l'anémie hémolytique auto-immune, des affections allergiques comprenant toutes les formes d'hypersensibilité. La présente invention concerne en outre des procédés pour traiter des cancers qui sont médiés, dépendants de ou associés à l'activité p110, comprenant mais non restreints à des leucémies, telles que la leucémie myéloïde aiguë (LMA), le syndrome myélodysplasique (SMD), des maladies myéloprolifératives (MPD), la leucémie myéloïde chronique (LMC), la leucémie lymphoblastique T aiguë (LLA-T), la leucémie lymphoblastique B aiguë (LLA-B), le lymphome non hodgkinien (LNH), le lymphome B et des tumeurs solides, telles que le cancer du sein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32037810P | 2010-04-02 | 2010-04-02 | |
PCT/US2011/030888 WO2011123751A2 (fr) | 2010-04-02 | 2011-04-01 | Composés hétérocycliques et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34212B1 true MA34212B1 (fr) | 2013-05-02 |
Family
ID=43982368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35338A MA34212B1 (fr) | 2010-04-02 | 2011-04-01 | Composés hétérocycliques et leurs utilisations |
Country Status (24)
Country | Link |
---|---|
US (1) | US8575183B2 (fr) |
EP (1) | EP2552908A2 (fr) |
JP (1) | JP2013540099A (fr) |
KR (1) | KR20130103309A (fr) |
CN (1) | CN103221403A (fr) |
AR (1) | AR081448A1 (fr) |
AU (1) | AU2011235031B2 (fr) |
BR (1) | BR112012025164A2 (fr) |
CA (1) | CA2793897A1 (fr) |
CL (1) | CL2012002769A1 (fr) |
CO (1) | CO6630161A2 (fr) |
CR (1) | CR20120562A (fr) |
EA (1) | EA201291005A1 (fr) |
IL (1) | IL222288A0 (fr) |
MA (1) | MA34212B1 (fr) |
MX (1) | MX2012011387A (fr) |
MY (1) | MY184620A (fr) |
PE (1) | PE20130339A1 (fr) |
SG (1) | SG184354A1 (fr) |
TN (1) | TN2012000449A1 (fr) |
TW (1) | TW201202219A (fr) |
UY (1) | UY33304A (fr) |
WO (1) | WO2011123751A2 (fr) |
ZA (1) | ZA201207341B (fr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
WO2011163195A1 (fr) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k |
AR084312A1 (es) | 2010-12-16 | 2013-05-08 | Genentech Inc | Compuestos triciclicos inhibidores de la pi3k y composiciones farmaceuticas |
CA2822070C (fr) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(phenyl substitue)ethyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k |
EP2673269A1 (fr) * | 2011-02-09 | 2013-12-18 | F.Hoffmann-La Roche Ag | Composés hétérocycliques en tant qu'inhibiteurs de pi3 kinase |
WO2012125629A1 (fr) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k |
WO2012135009A1 (fr) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k |
SG10201604682VA (en) * | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
DK2751109T3 (en) | 2011-09-02 | 2017-01-23 | Incyte Holdings Corp | HETEROCYCLYLAMINES AS PI3K INHIBITORS |
EA029473B1 (ru) | 2011-12-15 | 2018-03-30 | Новартис Аг | Применение ингибиторов pi3k для лечения острой и церебральной малярии |
WO2013130461A1 (fr) * | 2012-02-29 | 2013-09-06 | The Scripps Research Institute | Inhibiteurs de dégradation de wee1 |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
JP6259823B2 (ja) | 2012-07-13 | 2018-01-10 | ユーシービー バイオファルマ エスピーアールエル | Tnf活性の調節物質としてのイミダゾピリジン誘導体 |
JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
CA2895782C (fr) | 2012-12-21 | 2017-08-22 | Gilead Calistoga Llc | Pyrimidine aminoalkyl-quinazolones substituees en tant qu'inhibiteurs de phosphatidylinositol 3-kinase |
NZ708870A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
PL3008053T3 (pl) | 2013-06-14 | 2018-08-31 | Gilead Calistoga Llc | Inhibitory 3-kinazy fosfatydyloinozytolu |
CN104513235B (zh) * | 2013-09-02 | 2017-12-05 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
SG11201600028YA (en) * | 2013-09-22 | 2016-02-26 | Calitor Sciences Llc | Substituted aminopyrimidine compounds and methods of use |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
CN106470996B (zh) | 2014-07-04 | 2019-02-22 | 鲁平有限公司 | 作为pi3k抑制剂的喹嗪酮衍生物 |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
JP6586463B2 (ja) | 2014-12-19 | 2019-10-02 | ヤンセン ファーマシューティカ エヌ.ベー. | PI3Kβ阻害剤としての複素環連結イミダゾピリダジン誘導体 |
CN107108634B (zh) | 2014-12-19 | 2020-09-15 | 詹森药业有限公司 | 作为PI3Kβ抑制剂的咪唑并哒嗪衍生物 |
US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
TWI748941B (zh) | 2015-02-27 | 2021-12-11 | 美商英塞特公司 | Pi3k抑制劑之鹽及製備方法 |
WO2016134668A1 (fr) * | 2015-02-28 | 2016-09-01 | Sunshine Lake Pharma Co., Ltd. | Composés d'aminopyrimidine substituée et procédés d'utilisation |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
WO2016183060A1 (fr) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases |
WO2017060406A1 (fr) | 2015-10-09 | 2017-04-13 | Janssen Pharmaceutica Nv | Dérivés de quinoxaline et de pyridopyrazine à titre d'inhibiteurs de pi3kβ |
US11420944B2 (en) | 2016-01-12 | 2022-08-23 | Nippon Chemiphar Co., Ltd. | Voltage-dependent t-type calcium channel blocker |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA3025746A1 (fr) | 2016-06-16 | 2017-12-21 | Janssen Pharmaceutica Nv | Derives d'azabenzimidazole utilises comme inhibiteurs de pi3k beta |
EA037361B1 (ru) | 2016-06-16 | 2021-03-18 | Янссен Фармацевтика Нв | Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета |
EP3484877B1 (fr) | 2016-07-12 | 2020-07-01 | Bayer CropScience Aktiengesellschaft | Composes bicycliques comme pesticides |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
MX2019011610A (es) | 2017-03-29 | 2019-11-08 | Janssen Pharmaceutica Nv | Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta. |
US20230190717A1 (en) * | 2017-04-10 | 2023-06-22 | City Of Hope | P38 gamma inhibitors and method of use thereof |
WO2019058393A1 (fr) | 2017-09-22 | 2019-03-28 | Jubilant Biosys Limited | Composés hétérocycliques en tant qu'inhibiteurs de pad |
SG11202003463XA (en) | 2017-10-18 | 2020-05-28 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
CN111386265A (zh) | 2017-11-06 | 2020-07-07 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物 |
MX2020005363A (es) | 2017-11-24 | 2020-10-01 | Jubilant Episcribe Llc | Compuestos heterociclicos como inhibidores de prmt5. |
WO2019168847A1 (fr) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b |
EP3765453A1 (fr) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Composés bicycliques utilisés en tant qu'inhibiteurs de l'interaction/activation de pd1/pd-l1 |
EP3810610A1 (fr) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
KR20210049090A (ko) | 2018-07-05 | 2021-05-04 | 인사이트 코포레이션 | A2a/a2b 억제제로서 융합된 피라진 유도체 |
BR112021002280A2 (pt) | 2018-08-07 | 2021-05-04 | Syngenta Crop Protection Ag | compostos heteroaromáticos bicíclicos ativos em termos pesticidas |
US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
CN113557235A (zh) * | 2019-03-06 | 2021-10-26 | C4医药公司 | 用于药物治疗的杂环化合物 |
GB201909190D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
GB201909191D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
AU2021403015A1 (en) * | 2020-12-15 | 2023-08-03 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
US20240254121A1 (en) | 2021-05-06 | 2024-08-01 | Bayer Aktiengesellschaft | Alkylamide substituted, annulated imidazoles and use thereof as insecticides |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
CA1279648C (fr) * | 1986-07-11 | 1991-01-29 | Haruo Kuriyama | Derives 2-(4-pyridylaminomethyl)benzimidazole a activite antivirale |
EP0530149A1 (fr) * | 1991-08-30 | 1993-03-03 | Ciba-Geigy Ag | Parasiticide |
US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
WO2003040141A1 (fr) * | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Composes d'oxazolyl-phenyl-2,4-diamino-pyrimidine, et methodes de traitement de troubles hyperproliferatifs |
US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
PE20050068A1 (es) * | 2003-02-06 | 2005-03-11 | Novartis Ag | 2-cianopirrolopirimidinas como inhibidores de la catepsina s |
GT200500284A (es) * | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
AR060632A1 (es) * | 2006-04-26 | 2008-07-02 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso |
WO2008039882A1 (fr) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2 |
MX2010003449A (es) | 2007-09-26 | 2010-04-27 | Astellas Pharma Inc | Derivado de quinolona. |
EP2277881A4 (fr) * | 2008-04-18 | 2011-09-07 | Shionogi & Co | Composé hétérocyclique présentant une activité inhibitrice sur p13k |
GB0821693D0 (en) | 2008-11-27 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
ES2598358T3 (es) | 2009-02-13 | 2017-01-27 | Ucb Pharma, S.A. | Derivados de quinolina como inhibidores de PI3K quinasa |
EP2445900B1 (fr) | 2009-06-25 | 2016-03-02 | Amgen, Inc | Derives polycycliques de pyridine et leur utilisation dans le traitement de (entre autres) arthrite rhumatoïde et de troubles similaires |
MX2012006953A (es) | 2009-12-18 | 2012-10-09 | Amgen Inc | Compuestos heterociclicos y sus usos. |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
-
2011
- 2011-03-30 UY UY0001033304A patent/UY33304A/es not_active Application Discontinuation
- 2011-04-01 CA CA2793897A patent/CA2793897A1/fr not_active Abandoned
- 2011-04-01 SG SG2012072526A patent/SG184354A1/en unknown
- 2011-04-01 US US13/078,192 patent/US8575183B2/en active Active
- 2011-04-01 CN CN2011800269826A patent/CN103221403A/zh active Pending
- 2011-04-01 KR KR1020127028710A patent/KR20130103309A/ko not_active Application Discontinuation
- 2011-04-01 BR BR112012025164A patent/BR112012025164A2/pt not_active IP Right Cessation
- 2011-04-01 MA MA35338A patent/MA34212B1/fr unknown
- 2011-04-01 MY MYPI2012004234A patent/MY184620A/en unknown
- 2011-04-01 AR ARP110101102A patent/AR081448A1/es not_active Application Discontinuation
- 2011-04-01 WO PCT/US2011/030888 patent/WO2011123751A2/fr active Application Filing
- 2011-04-01 EA EA201291005A patent/EA201291005A1/ru unknown
- 2011-04-01 AU AU2011235031A patent/AU2011235031B2/en not_active Expired - Fee Related
- 2011-04-01 MX MX2012011387A patent/MX2012011387A/es not_active Application Discontinuation
- 2011-04-01 EP EP11713167A patent/EP2552908A2/fr not_active Withdrawn
- 2011-04-01 JP JP2013502882A patent/JP2013540099A/ja not_active Withdrawn
- 2011-04-01 PE PE2012001829A patent/PE20130339A1/es not_active Application Discontinuation
- 2011-04-01 TW TW100111649A patent/TW201202219A/zh unknown
-
2012
- 2012-09-18 TN TNP2012000449A patent/TN2012000449A1/en unknown
- 2012-10-01 ZA ZA2012/07341A patent/ZA201207341B/en unknown
- 2012-10-02 CL CL2012002769A patent/CL2012002769A1/es unknown
- 2012-10-09 IL IL222288A patent/IL222288A0/en unknown
- 2012-10-30 CO CO12195413A patent/CO6630161A2/es active IP Right Grant
- 2012-11-02 CR CR20120562A patent/CR20120562A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MY184620A (en) | 2021-04-09 |
EA201291005A1 (ru) | 2013-09-30 |
CN103221403A (zh) | 2013-07-24 |
CA2793897A1 (fr) | 2011-10-06 |
CL2012002769A1 (es) | 2013-07-05 |
AU2011235031A1 (en) | 2012-10-25 |
US8575183B2 (en) | 2013-11-05 |
EP2552908A2 (fr) | 2013-02-06 |
JP2013540099A (ja) | 2013-10-31 |
CO6630161A2 (es) | 2013-03-01 |
TW201202219A (en) | 2012-01-16 |
US20110245257A1 (en) | 2011-10-06 |
CR20120562A (es) | 2013-03-01 |
BR112012025164A2 (pt) | 2016-06-21 |
KR20130103309A (ko) | 2013-09-23 |
ZA201207341B (en) | 2014-06-25 |
WO2011123751A2 (fr) | 2011-10-06 |
UY33304A (es) | 2011-10-31 |
PE20130339A1 (es) | 2013-04-13 |
AR081448A1 (es) | 2012-09-05 |
WO2011123751A3 (fr) | 2014-08-07 |
TN2012000449A1 (en) | 2014-01-30 |
IL222288A0 (en) | 2012-12-31 |
MX2012011387A (es) | 2013-02-26 |
AU2011235031B2 (en) | 2014-10-23 |
SG184354A1 (en) | 2012-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34212B1 (fr) | Composés hétérocycliques et leurs utilisations | |
EA201270013A1 (ru) | Гетероциклические соединения и их применение | |
MA37472A1 (fr) | Composés hétérocycliques et leurs utilisations | |
EA200901276A1 (ru) | Гетероциклические соединения и их применение | |
MX2009010050A (es) | Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k). | |
MX2011013901A (es) | Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k. | |
MX2009009913A (es) | Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres. | |
MX2012015135A (es) | Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. | |
MX2011013666A (es) | Compuestos heterociclicos y sus usos. | |
WO2010151737A3 (fr) | Composés hétérocycliques et leurs utilisations | |
MX2012015143A (es) | Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta. | |
EP4397665A3 (fr) | Polymorphe de diaryle macrocycle | |
MXPA05009595A (es) | Compuestos 7-amino-isoindolilo y sus usos farmaceuticos. | |
MX370000B (es) | Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3. | |
EA201100524A1 (ru) | Азаиндазолы в качестве антагонистов рецептора ccr1 | |
MX2019007708A (es) | Nuevos agentes anti-inflamatorios. | |
PL1699800T3 (pl) | Bicykliczne heterocykliczne inhibitory kinazy p-38 | |
MX2009003125A (es) | Tiazol pirazolopirimidinas como antagonistas de receptor de crf1. | |
EA200970302A1 (ru) | Тиофенпиразолопиримидиновые соединения | |
WO2019226213A3 (fr) | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y | |
WO2018033941A3 (fr) | Compositions pharmaceutiques à base d'ibrutinib | |
MXPA05003718A (es) | Compuestos x-nitro, sus composiciones farmaceuticas y sus usos. | |
AU2019296851A8 (en) | Application of composition of D-mannuronic diacid in treatment of Parkinson's disease | |
CY1117196T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
WO2005037208A3 (fr) | Promedicaments a base de composes nitrones, et compositions pharmaceutiques correspondantes permettant de traiter des troubles chez l'homme |